MTRI

15.47011.60%

Mentari Therapeutics surges 16%

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Mentari Therapeutics (MTRI.US) surged more than 16% during regular trading to $14.16.

The Nasdaq Composite is down 1.48% over the past five sessions.

The company completed its merger with InMed Pharmaceuticals on Nov. 6, 2026, and released pro forma combined financial statements. As of June 30, 2026, total cash stood at $478.12 million, total assets at $478.78 million and liabilities at $11.42 million. The net loss was $37.29 million in the first half of 2026, compared with $26.90 million for the full year 2025.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Recommended Readings